Clinical Trials
38 trialsRA-DRUM
Diakonhjemmet Hospital
A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
Biocad
BIOSTOP
Helse Møre og Romsdal HF
DUET
Janssen Research & Development, LLC
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
The Affiliated Hospital Of Guizhou Medical University
REALISE
NHS Greater Glasgow and Clyde
FREE
University Medical Center Groningen
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
University of Michigan
RIDD
University of Oxford
STARA
Georgetown University
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Amgen
BIORA-PAIN
St George's, University of London
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
CALYPSO
Biocad
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
HIBISCUS I
Hoffmann-La Roche
HIBISCUS II
Hoffmann-La Roche
Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients
Universidade Nova de Lisboa
Trial of Adalimumab in Progressive Sarcoidosis
University of Chicago
Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers
Innovent Biologics (Suzhou) Co. Ltd.
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
AbbVie
Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis
Innovent Biologics (Suzhou) Co. Ltd.
CLEAR
AbbVie
PIONEER (OLE)
AbbVie
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
MOA
Tufts Medical Center
SWITCH
University of Leeds
Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"
Central South University
AUGUST II
EMD Serono
TAM-RT
Gustave Roussy, Cancer Campus, Grand Paris
Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis
Chung Shan Medical University
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Hoffmann-La Roche
DORA
Assistance Publique - Hôpitaux de Paris
OPTIMA
Abbott
ATLAS
Abbott
PETRA
University Hospital, Tours
HURRAH
Hvidovre University Hospital